CD14 Polymorphism Is Not Associated with SARS-CoV-2 Infection in Central European Population

HUBACEK, Jaroslav A., Tom PHILIPP, Ondřej MÁJEK, Dana DLOUHA, Vera ADAMKOVA and Ladislav DUŠEK. CD14 Polymorphism Is Not Associated with SARS-CoV-2 Infection in Central European Population. Folia biologica. Prague: Charles University, 2023, vol. 69, 5-6, p. 181-185. ISSN 0015-5500. Available from: https://dx.doi.org/10.14712/fb2023069050181.

Basic information

• Original name: CD14 Polymorphism Is Not Associated with SARS-CoV-2 Infection in Central European Population
• Authors: HUBACEK, Jaroslav A. (203 Czech Republic), Tom PHILIPP (203 Czech Republic), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Dana DLOUHA (203 Czech Republic), Vera ADAMKOVA (203 Czech Republic) and Ladislav DUŠEK (203 Czech Republic, belonging to the institution).
• Edition: Folia biologica, Prague, Charles University, 2023, 0015-5500.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30304 Public and environmental health
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 0.600 in 2022
• RIV identification code: RIV/00216224:14110/23:00134792
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.14712/fb2023069050181
• UT WoS: 001199526300002
• Keywords in English: COVID-19; CD14; polymorphism; SARS-CoV-2
• Tags: 14119612, rivok

Abstract

A 2021 in silico study highlighted an association between the CD14 polymorphism rs2569190 and increased susceptibility to SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19). The aim of our study was to confirm this finding. We analysed the CD14 polymorphism (C -> T; rs2569190) in 516 individuals who tested positive for SARS-CoV-2, with differing disease severity (164 asymptomatic, 245 symptomatic, and 107 hospitalized). We then compared these patients with a sample from the general population consisting of 3,037 individuals using a case -control study design. In comparison with carriers of the C allele, TT homozygotes accounted for 21.7 % of controls and 20.5 % in SARS-CoV-2positive individuals (P = 0.48; OR; 95 % CI - 0.92; 0.73-1.16). No significant differences in the distribution of genotypes were found when considering codominant and recessive genetic models or various between -group comparisons. The CD14 polymor phism is unlikely to be an important predictor of COVID-19 in the Caucasian population in Central Europe.